Infectious Disease Clinical Trial Award: Optimising interventions for impact

This funding call will support transdisciplinary teams led from Africa, South Asia or South-East Asia to conduct randomised controlled trials that optimise licensed pharmaceutical interventions for infectious diseases. 

The clinical trial should generate evidence to inform changes to policy, practice and guidelines, and lead to measurable impact in the communities most affected, ultimately improving the treatment and prevention of infectious diseases in low- and middle-income countries. 

Disease areas

The pharmaceutical intervention (vaccine or therapeutic) must focus on one of the following disease areas:

• mycobacterial infections (tuberculosis, leprosy or infections with non-tuberculous mycobacteria)
• bacterial infections (sexually transmitted infections, lower respiratory tract infections or bloodstream infections) 
• invasive fungal infections 
• dengue, leishmaniasis or schistosomiasis